XC 001

Drug Profile

XC 001

Alternative Names: AdVEGF-A116A+ gene therapy - XyloCor Therapeutics; XC001

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornell University
  • Developer Cornell University; XyloCor Therapeutics
  • Class Cardiovascular therapies; Gene therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Angina pectoris

Most Recent Events

  • 08 May 2017 XC 001 licensed to XyloCor Therapeutics worldwide
  • 08 May 2017 Preclinical trials in Angina pectoris (Treatment-resistant) in USA (unspecified route)
  • 08 May 2017 XC 001 receives Fast Track designation for Angina pectoris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top